<DOC>
	<DOCNO>NCT01778049</DOCNO>
	<brief_summary>The objective study investigate efficacy , safety tolerability linagliptin 5 mg qd compare placebo give 24 week inadequately control T2DM patient empagliflozin 10 mg 25 mg maximum tolerate dose metformin . The primary objective efficacy evaluation plan 24 week treatment . The study design show superiority combination empagliflozin linagliptin empagliflozin alone .</brief_summary>
	<brief_title>Linagliptin Add Therapy Empagliflozin 10 mg 25 mg With Background Metformin Patient With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed dated ICF ( Informed Consent Form ) 2 . Male female diet exercise regime stable background metformin &gt; equal 1500 mg maximun dose accord local label 3 . HBA1c ( Glicoslated Hemoglobin ) &gt; equal 8 % &lt; equal 10.5 % Visit 1 4 . HbA1c &gt; equal 7 &lt; equal 10.5 Visit 4 5 . Age &gt; equal 18 year 6 . BMI ( Body Mass Index ) &lt; equal 45 Exclusion criterion : 1 . Uncontrolled hyperglycemia open label period placebo add `` runin '' period 2 . Use antidiabetic 3 . Renal function 60 ml/min/1.73 m2 4 . Antiobesity drug aggresive diet 5 . Gastorintestinal surgery 6 . Current systemic steroid uncontrolled endocrine disorder Diabetes Type 2 7 . Acute coronary syndrome stroke within 3 month inform consent 8 . Known allergy DPPIV ( Dypeptidil Peptidase IV ) SGLT2 ( Sodium Glucose Transporter 2 ) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>